Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty

Frailty is a syndrome associated with reduced physiological reserves that increases an individual's vulnerability for developing increased morbidity and/or mortality. While most clinical trials have focused on exercise, nutrition, pharmacologic agents, or a multifactorial approach for the preve...

Descripción completa

Detalles Bibliográficos
Autores principales: Golpanian, Samuel, DiFede, Darcy L., Pujol, Marietsy V., Lowery, Maureen H., Levis-Dusseau, Silvina, Goldstein, Bradley J., Schulman, Ivonne H., Longsomboon, Bangon, Wolf, Ariel, Khan, Aisha, Heldman, Alan W., Goldschmidt-Clermont, Pascal J., Hare, Joshua M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper: Gerotarget (Focus on Aging)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914257/
https://www.ncbi.nlm.nih.gov/pubmed/26933813
http://dx.doi.org/10.18632/oncotarget.7727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914257/
https://www.ncbi.nlm.nih.gov/pubmed/26933813
http://dx.doi.org/10.18632/oncotarget.7727

Ejemplares similares